Tag: Cancer: Kidney

Findings seen for 240 counties in Texas when accounting for demographic, socioeconomic factors and cancer risk factors

In a recent study, mean sensitivity was 85.5 percent and specificity 87 percent for detection of clear-cell renal cell carcinoma

No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting

Disparities seen based on income, education, and insurance status for both advanced kidney, bladder cancer

Belzutifan beneficial for advanced clear cell renal cell carcinoma patients who had previously received immune checkpoint, antiangiogenic therapies

Validated polygenic risk score generated, with area under the curve of 0.65 among European ancestry individuals

Disease-free survival benefit was consistent with that seen in previous analyses; improvement in overall survival also seen

Patients with stromal-predominant tumors had the youngest age at diagnosis compared with other histologic subtypes

Significant improvement seen in overall survival with pembrolizumab versus placebo and across key subgroups

Findings seen in clear cell renal cell carcinoma patients at very high disease risk after nephrectomy from EVEREST trial